Concerns about the ALIFE2 trial

Affiliations

¹ Division of Blood Transfusion, Shinshu University Hospital, Nagano, Japan.
² Division of Cell Transplantation and Transfusion, Jichi Medical University Hospital, Tochigi, Japan.
³ Division of Transfusion Medicine and Cell Therapy, The Jikei University Hospital, Tokyo 1058471, Japan. Electronic address: tomosatou@jikei.ac.jp.

Comment

Ryu Yanagisawa et al. Lancet. 2024.

. 2024 Jan 20;403(10423):246-247.

doi: 10.1016/S0140-6736(23)02339-5.

¹ Division of Blood Transfusion, Shinshu University Hospital, Nagano, Japan.
² Division of Cell Transplantation and Transfusion, Jichi Medical University Hospital, Tochigi, Japan.
³ Division of Transfusion Medicine and Cell Therapy, The Jikei University Hospital, Tokyo 1058471, Japan. Electronic address: tomosatou@jikei.ac.jp.

No abstract available

Comment in

Concerns about the ALIFE2 trial - Authors' reply.
Quenby S, Ewington L, Hamulyák E, Scheres LJ, Goddijn M, Middeldorp S. Quenby S, et al. Lancet. 2024 Jan 20;403(10423):248. doi: 10.1016/S0140-6736(23)02336-X. Lancet. 2024. PMID: 38245246 No abstract available.

Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial.
Quenby S, Booth K, Hiller L, Coomarasamy A, de Jong PG, Hamulyák EN, Scheres LJ, van Haaps TF, Ewington L, Tewary S, Goddijn M, Middeldorp S; ALIFE2 Block Writing Committee; ALIFE2 Investigators. Quenby S, et al. Lancet. 2023 Jul 1;402(10395):54-61. doi: 10.1016/S0140-6736(23)00693-1. Epub 2023 Jun 1. Lancet. 2023. PMID: 37271152 Clinical Trial.